10 April 2026
LONDON STOCK EXCHANGE ANNOUNCEMENT THE MERCANTILE INVESTMENT TRUST PLC FINAL RESULTS FOR THE YEAR ENDED 31ST JANUARY 2026 Legal Entity Identifier: 549300BGX3CJIHLP2H42 Information disclosed in…
8 April 2026
Board Changes Renishaw plc (“Company”), a leading provider of manufacturing technologies, analytical instruments and medical devices, announces the following changes to its Board of…
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) GSK plc (LSE/NYSE: GSK) today announced that China’s National Medical…
YOUNG & CO.’S BREWERY, P.L.C. (“Young’s”) Young’s to acquire Cubitt House Young’s, the premium operator of pubs and bedrooms in London and the South…
2 April 2026
SSE plc Trading Update 2 April 2026 Ahead of the publication on 28 May 2026 of results for the full year ended 31 March…
THE MERCHANTS TRUST PLC LEI: 5299008VJFXCUD2EG312 FINAL RESULTS FOR THE YEAR ENDED 31 JANUARY 2026 The following comprises extracts from the company’s Annual Report…
Murray Income Trust PLC (“the Company”) Legal Entity Identifier (LEI): 549300IRNFGVQIQHUI13 2 April 2026 Update on Transition of Portfolio Holdings The Board of Murray Income…
Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial Imfinzi plus…